A separate operational update from the CDMO landscape highlighted how contract manufacturers are adding capacity and quality infrastructure while incorporating digital systems for data integrity. The roundup pointed to Fujifilm’s QC laboratory expansion and workflow modernization, including robotics and rollout of a laboratory information management system (LIMS). In parallel, the coverage ties these upgrades to FDA-facing programs intended to streamline readiness and quality verification during manufacturing scale-up. For sponsors, digital harmonization can reduce variability across sites and speed release decisions. Taken together, the operational investments signal that near-term supply risk management is moving from capacity alone to execution quality—testing, potency assays, and viral safety governance. The practical consequence is that sponsors may increasingly screen CDMOs on both throughput and compliance tooling when planning late-stage production.